Article Dans Une Revue Rheumatology Année : 2024

How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients

Conor Coyle
Lily Watson
Caroline Whately-Smith
  • Fonction : Auteur
Mel Brooke
  • Fonction : Auteur
Uta Kiltz
Ennio Lubrano
Ruben Queiro
David Trigos
  • Fonction : Auteur
Jan Brandt-Juergens
  • Fonction : Auteur
Ernest Choy
Salvatore D’angelo
  • Fonction : Auteur
Andrea Delle Sedie
  • Fonction : Auteur
Emmanuelle Dernis
  • Fonction : Auteur
Sandrine Guis
Philip Helliwell
Pauline Ho
  • Fonction : Auteur
Axel Hueber
  • Fonction : Auteur
Beatriz Joven
  • Fonction : Auteur
Michaela Koehm
  • Fonction : Auteur
Carlos Montilla Morales
  • Fonction : Auteur
Jon Packham
  • Fonction : Auteur
Jose Antonio Pinto Tasende
  • Fonction : Auteur
Julio Ramírez
  • Fonction : Auteur
Adeline Ruyssen-Witrand
  • Fonction : Auteur
Rossana Scrivo
Sarah Twigg
  • Fonction : Auteur
Martin Welcker
  • Fonction : Auteur
Martin Soubrier
Laura C Coates

Résumé

Abstract Objectives The AsseSSing Impact in pSoriatic Treatment (ASSIST) study investigated prescribing in routine PsA care and whether the patient-reported outcome—PsA Impact of Disease questionnaire (PsAID-12)—impacted treatment. This study also assessed a range of patient and clinician factors and their relationship to PsAID-12 scoring and treatment modification. Methods Patients with PsA were selected across the UK and Europe between July 2021 and March 2022. Patients completed the PsAID questionnaire and the results were shared with their physician. Patient characteristics, disease activity, current treatment methods, treatment strategies, medication changes and patient satisfaction scores were recorded. Results A total of 503 patients were recruited. Some 36.2% had changes made to treatment, and 88.8% of these had treatment escalation. Overall, the mean PsAID-12 score was higher for patients with treatment escalation; increase in PSAID-12 score is associated with increased odds of treatment escalation (odds ratio 1.58; P < 0.0001). However, most clinicians reported that PsAID-12 did not impact their decision to escalate treatment, instead supporting treatment reduction decisions. Physician’s assessment of disease activity had the most statistically significant effect on likelihood of treatment escalation (odds ratio 2.68, per 1-point score increase). Escalation was more likely in patients not treated with biologic therapies. Additional factors associated with treatment escalation included: patient characteristics, physician characteristics, disease activity and disease impact. Conclusion This study highlights multiple factors impacting treatment decision-making for individuals with PsA. PsAID-12 scoring correlates with multiple measures of disease severity and odds of treatment escalation. However, most clinicians reported that the PsAID-12 did not influence treatment escalation decisions. Psoriatic Arthritis Impact of Disease (PsAID) scoring could be used to increase confidence in treatment de-escalation.

Fichier principal
Vignette du fichier
2023 Coyle Rheumatology how do PROs affect treatment in PsA ASSIST.pdf (649.75 Ko) Télécharger le fichier
Origine Publication financée par une institution
Licence

Dates et versions

hal-04564086 , version 1 (30-04-2024)

Licence

Identifiants

Citer

Conor Coyle, Lily Watson, Caroline Whately-Smith, Mel Brooke, Uta Kiltz, et al.. How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. Rheumatology, 2024, ⟨10.1093/rheumatology/kead679⟩. ⟨hal-04564086⟩
172 Consultations
303 Téléchargements

Altmetric

Partager

  • More